14 November 2022 | Monday | News
Image Source : Public Domain
Results of the third quarter of 2022
Forecast for fiscal 2022
Merck, a leading science and technology company, continued to grow in the third quarter of 2022 despite a challenging external operating environment. Group sales increased by 16.8% to € 5,806 million. The “Big 3” – Process Solutions and Life Science Services, new Healthcare products as well as Semiconductor Solutions – were the key drivers of the strong, 7.1% organic increase in sales. Despite higher costs for raw materials, energy and logistics, EBITDA pre rose organically by 7.5% to € 1,810 million. Higher earnings in the Life Science and Healthcare business sectors contributed to this increase in EBITDA pre.
For fiscal 2022, Merck confirms the mid-point of the absolute ranges for sales, EBITDA pre and EPS pre for the Group level. The company has raised its expectation for organic growth of EBITDA pre of the Life Science business sector yet is lowering it for the Electronics business sector.
“Despite the ongoing turbulence in our external operating environment, we’ve demonstrated our resilience and delivered strong organic growth in sales and EBITDA pre in the third quarter of 2022,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “All three of our business sectors are well-positioned. In Life Science, the core business delivered double-digit growth, more than offsetting the expected decline in pandemic-related sales. The new products and the established portfolio in Healthcare performed strongly. And in Electronics, the renewed double-digit growth of Semiconductor Solutions justifies our confidence in this business.”